Dr. Wen Wang has over a decade of deep expertise in CAR-T cell therapy. He focuses on end-to-end R&D and commercialization of cell therapy products, with extensive hands-on industrial and manufacturing experience.
During his career, Dr. Wang led and participated in the clinical development of two landmark CAR-T therapies in China, including Relmacabtagene autoleucel (Carteyva®), China’s second CD19 CAR-T product, and Equecabtagene autoleucel (Fucaso®), China’s first BCMA CAR-T product.
Building on solid technical know-how and industrial insights, Dr. Wang continues to advance innovative research in cellular immunotherapies. He is committed to developing safer, more potent and accessible next-generation cell therapy technologies and products, and driving high-quality growth of China’s cell therapy industry.
